Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.64 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.63 |
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840083 | 1.00 | KCNH2 (0.64) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4839583 | 0.89 | KCNH2 (0.64) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4839594 | 0.89 | KCNH2 (0.64) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4842109 | 0.89 | KCNH2 (0.67) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4842124 | 0.89 | KCNH2 (0.67) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4838340 | 0.87 | KCNH2 (0.70) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4838319 | 0.87 | KCNH2 (0.70) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4838400 | 0.87 | KCNH2 (0.70) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4842018 | 0.87 | KCNH2 (0.70) | KCNH2SCN9ASCN5AHTR2ADRD2 | |
| SCHEMBL4838380 | 0.87 | KCNH2 (0.70) | KCNH2SCN9ASCN5AHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025095-B1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 2003-11-26 | — | — | EP | claimed |
| US-20030100556-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2003-05-29 | — | — | US | claimed |
| US-6479497-B1 | COMPOUNDS HAVING A SELECTIVE EFFECT AT A SUBGROUP OF 5-HYDROXYTRYPTAMINE RECEPTORS, DESIGNATED THE H5-HT1B RECEPTOR | ASTRAZENECA AB (SE) | 2002-11-12 | — | — | US | claimed |
| EP-1025095-A1 | SUBSTITUTED CHROMAN DERIVATIVES | AstraZeneca AB (SE) | 2000-08-09 | — | — | EP | claimed |
| WO-1999014212-A1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | claimed |
| US-7384943-B2 | Substituted chroman derivatives | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20060223828-A1 | piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives; serotonin h5-HT1B receptor antagonist; regulate the synaptic concentration of serotonin by controlling the amount of 5-HT that is released; anxiolitic, antidepressant | BERG STEFAN | 2006-10-05 | — | — | US | disclosed |
| US-7056921-B2 | Substituted chroman derivatives | ASTRAZANECA AB (SE) | 2006-06-06 | — | — | US | disclosed |
| US-20040157857-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2004-08-12 | — | — | US | disclosed |
| US-6670359-B2 | Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders | ASTRAZENECA AB (SE) | 2003-12-30 | — | — | US | disclosed |
| EP-1025095-B1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 2003-11-26 | — | — | EP | disclosed |
| US-20030100556-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2003-05-29 | — | — | US | disclosed |
| US-6479497-B1 | COMPOUNDS HAVING A SELECTIVE EFFECT AT A SUBGROUP OF 5-HYDROXYTRYPTAMINE RECEPTORS, DESIGNATED THE H5-HT1B RECEPTOR | ASTRAZENECA AB (SE) | 2002-11-12 | — | — | US | disclosed |
| EP-1025095-A1 | SUBSTITUTED CHROMAN DERIVATIVES | AstraZeneca AB (SE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999014212-A1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100556-A1 | Substituted chroman derivatives | NR2C2, NR0B1, NR0B2 | KCNH2 857/4885SCN9A 1092/4885SCN5A 905/4885 |
| US-20060223828-A1 | piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives; serotonin h5-HT1B receptor antagonist; regulate the synaptic concentration of serotonin by controlling the amount of 5-HT that is released; anxiolitic, antidepressant | HTR2B, HTR2C, HTR2A | KCNH2 529/4885SCN9A 829/4885SCN5A 466/4885 |
| US-20040157857-A1 | Substituted chroman derivatives | NR2C2, NR0B1, NR0B2 | KCNH2 857/4885SCN9A 1092/4885SCN5A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.